GSK1349572; efavirenz
Проводит ViiV Healthcare
Страница компанииA Phase IIb Study to Select a Once Daily Dose of GSK1349572 Administered With Either Abacavir/Lamivudine or Tenofovir/Emtricitabine in HIV-1 Infected Antiretroviral Therapy Naive Adult Subjects
Постоянная ссылка: https://clinomir.ru/trials/nct/NCT00951015/
Источник: ClinicalTrials.gov (U.S. National Library of Medicine). Что откуда
Простыми словами
Словарь терминов- Фаза II — препарат уже прошёл первую проверку безопасности. Проверяют, действует ли он при этом заболевании, и уточняют дозу.
- Исследование завершено, новых участников не набирают.
- Возраст участников: от 18 лет. Остальные условия — в блоке «Кто может участвовать».
- По плану участвуют 208 чел. во всех странах исследования.
- Плановая дата окончания (12.2016) уже прошла.
Пересказ собран автоматически из данных реестра, без оценки пользы и рисков. Подробно о рисках и пользе рассказывает врач центра перед подписанием согласия.
Кто может участвовать
Главное из критериев
- ИнфекцииВИЧ, гепатит B или C упомянуты в критериях невключения
Выбрано из текста реестра автоматически, по правилам — без ИИ. Решение об участии принимает врач центра по полному протоколу.
Полный текст критериев (на английском, как в ClinicalTrials.gov) · включение: 9 · невключение: 22
Критерии включения
- HIV-1 infected male or female adults at least 18 years of age. Women capable of becoming pregnant must use appropriate contraception during the study (as defined by the protocol);
- HIV-1 infection with a screening plasma HIV-1 RNA greater than or equal to 1000copies/mL;
- CD4+ cell count greater than or equal to 200cells/mm3 (or higher as local guidelines dictate);
- ART-naive (less than or equal to 10 days of prior therapy with any antiretroviral agent). Any previous exposure to an HIV integrase inhibitor other than GSK1349572 will be exclusionary.
- No evidence of viral resistance to any antiretroviral drug indicative of primary transmitted resistance at screening;
- Able to understand and comply with protocol requirements;
- Able to provide written informed consent prior to screening;
- French subjects: In France, a subject will be eligible for inclusion in this study only if either affiliated to or a beneficiary of a social security category.
- Note: Subjects starting abacavir as part of the NRTI backbone must have been screened and be negative for the HLA-B*5701 allele.
Критерии невключения
- Any pre-existing or serious mental or physical disorder which could compromise ability to comply with the protocol or compromise subject safety;
- Women who are pregnant or breastfeeding;
- An active AIDS-defining condition at the screening visit;
- Previous participation in an experimental drug and/or vaccine trial(s) within 30 days or 5 half-lives;
- History of clinically relevant pancreatitis or hepatitis within the previous 6 months, including HBsAg positive result. Asymptomatic HCV infection will not be exclusionary, however subject who will require HCV therapy during the trial should be excluded. Any subject with a history of liver cirrhosis with or without hepatitis viral co-infection will be excluded.
- Any condition which could interfere with the absorption, distribution, metabolism or excretion of the drug;
- Any acute or Grade 4 laboratory abnormality at screening;
- History of upper gastrointestinal bleed and/or subjects with active peptic ulcer disease;
- Estimated creatinine clearance <50 mL/min;
- Alanine aminotransferase (ALT) greater than or equal to 5 times ULN;
- Alanine aminotransferase (ALT) greater than or equal to 3xULN and bilirubin greater than or equal to 1.5xULN (with >35% direct bilirubin);
- Lipase greater than or equal to 3xULN;
- Hemoglobin < 100 g/L(10 g/dL);
- History of allergy to the study drugs or their components or drugs of their class;
- Treatment with radiation therapy, cytotoxic chemotherapeutic agents, any agents with activity against HIV-1 or immunomodulators within 28 days prior to screening;
- Treatment with an HIV-1 immunotherapeutic vaccine within 90 days prior to screening;
- History of protocol-defined cardiac diseases;
- Personal or family history of prolonged QT syndrome;
- Any clinically significant finding, as specified in the protocol, on electrocardiograph (ECG);
- Significant blood loss in excess of 500 mL within a 56 day period prior to screening visit;
- Immunization within 30 days prior to first dose of investigational product;
- French subjects: The subject has participated in any study using an investigational drug during the previous 60 days or 5 half-lives, or twice the duration of the biological effect of the experimental drug or vaccine - whichever is longer, prior to screening for the study or the subject will participate simultaneously in another clinical study.
Источник: ClinicalTrials.gov, NCT00951015 · запись обновлена в реестре 16 января 2018.
Дизайн и результаты
Что измеряют — первичные конечные точки (1), вторичных — 21
- Number of Participants With Human Immunodeficiency Virus Type 1 (HIV-1) Ribonucleic Acid (RNA) <50 Copies/Milliliter (c/mL) at Week 16 — Week 16
Цель исследования
This Phase IIb study in HIV-infected antiretroviral naive subjects will select an optimal once daily dose of GSK1349572 from a range of doses for future evaluation.
Где проходит
0 центровЦентры в реестре не указаны.
Откуда эта информация
-
ClinicalTrials.gov (U.S. National Library of Medicine) · NCT00951015 Официальный реестр (США) · загружено 9 ноября 2026Препарат, номер протокола, название, цель, фаза, статус, сроки, число участников, спонсор
Сведения сведены и нормализованы порталом «Клиномир»: названия компаний и центров приведены к одному написанию. Нашли ошибку? Напишите нам — исправим.